(Q46575274)

23 December 2017

title

Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer (English)

1 reference

23 December 2017

author name string

David J Reeves

series ordinal

1

1 reference

23 December 2017

Daniel J Bestul

series ordinal

2

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

23 December 2017

published in

Pharmacotherapy

1 reference

23 December 2017

volume

28

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

page(s)

685-690

1 reference

23 December 2017

Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.685

Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.685

Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.685

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.685

Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.685

Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.685

Treatment of impending tumor lysis with single-dose rasburicase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.685

Use of single-dose rasburicase in an obese female

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.685

Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.685

A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.685

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.685

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.6.685

1 reference

23 December 2017

1 reference

23 December 2017